Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630617 | 0.81 | FFAR4 (0.53) | PTPN1GPR84FFAR4FFAR1CAMK2A | |
| SCHEMBL446026 | 0.81 | FFAR4 (0.53) | PTPN1GPR84FFAR4FFAR1CAMK2A | |
| SCHEMBL31512908 | 0.79 | FFAR4 (0.57) | PTPN1GPR84FFAR4FFAR1ACACB | |
| SCHEMBL15541850 | 0.79 | FFAR4 (0.57) | PTPN1GPR84FFAR4FFAR1ACACB | |
| SCHEMBL17583231 | 0.78 | PTPN1 (0.44) | PTPN1GPR84FFAR4FFAR1ACACB | |
| SCHEMBL31512910 | 0.78 | GPR84 (0.43) | PTPN1GPR84FFAR4FFAR1ACACB | |
| SCHEMBL13912833 | 0.76 | THRB (0.43) | GPR84MAPK1SLC13A3EGLN1OR51E2 | |
| SCHEMBL18955820 | 0.75 | FFAR1 (0.70) | PTPN1GPR84FFAR4FFAR1NFKB1 | |
| SCHEMBL6838371 | 0.75 | FFAR1 (0.70) | PTPN1GPR84FFAR4FFAR1NFKB1 | |
| SCHEMBL19351243 | 0.75 | FFAR1 (0.70) | PTPN1GPR84FFAR4FFAR1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191129-A1 | WATER-BASED FRICTION-REDUCING SLURRY COMPOSITIONS, FORMATION TREATING FLUIDS THEREFROM, AND METHOD FOR MAKING AND USING SAME | PfP Industries LLC (US) | 2024-06-13 | — | — | US | claimed |
| US-20250035527-A1 | MODELING OPTIMIZED FRICTION REDUCING COMPOSITIONS FOR DOWNHOLE FLUID COMPOSITIONS AND METHODS OF MAKING AND USING | PfP Industries LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250034959-A1 | APPARATUSES AND SYSTEMS FOR IN-LINE WATER ANALYSIS, DOWNHOLE FLUID OPTIMIZATION, AND METHODS FOR MAKING AND USING SAME | PfP Industries LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240191129-A1 | WATER-BASED FRICTION-REDUCING SLURRY COMPOSITIONS, FORMATION TREATING FLUIDS THEREFROM, AND METHOD FOR MAKING AND USING SAME | PfP Industries LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20230398132-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | GREENWOOD BRANDS, LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11771708-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | GREENWOOD BRANDS, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11648257-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | PLX OPCO INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4125820-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF PH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | PLx Opco Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115666523-A | Drug carriers capable of pH dependent reconstitution and methods of making and using the same | PLX 奥普科有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220168321-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | PLX OPCO INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220000886-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | PLX OPCO INC. (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021195319-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME | PLX OPCO INC. (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000886-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | ABCB11, SLC47A1, SLC46A1 | PTPN1 340/4885GPR84 1772/4885FFAR4 1765/4885 |
| US-20220168321-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | ABCB11, SLC47A1, SLC46A1 | PTPN1 340/4885GPR84 1772/4885FFAR4 1765/4885 |
| US-20230398132-A1 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | ABCB11, SLC47A1, SLC46A1 | PTPN1 340/4885GPR84 1772/4885FFAR4 1765/4885 |
| US-11648257-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | ABCB11, SLC47A1, SLC46A1 | PTPN1 340/4885GPR84 1772/4885FFAR4 1765/4885 |
| US-11771708-B2 | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same | ABCB11, SLC47A1, SLC46A1 | PTPN1 340/4885GPR84 1772/4885FFAR4 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.